Inhibition LC3B can increase chemosensitivity of ovarian cancer cells

Cancer Cell International

Jing Tang¹  Dan Kong²  Yuguang Ye²  Jiang Zhu³  Cong Qiao⁴  Yu Liu⁴  Lei Zhang⁴  Xinxin Feng⁴  Yanni Kan⁴  Xiaobo Li⁴  Junyi Li⁴  Dai Tang⁴  Yan He⁴  Xiaoming Jin⁴ 

[1] Department of Bioinformatics, Southern Medical University;Department of Gynecology, Harbin Medical University Cancer Hospital;Department of Orthopedics, First Affiliated Hospital of Harbin Medical University;Department of Pathology, Harbin Medical University;

关键词: LC3B;    miR-204;    Ovarian cancer;    Autophagy;    Drug resistance;   

DOI  :  10.1186/s12935-019-0921-z

来源: DOAJ

【 摘 要 】

Abstract Background Ovarian cancer is often accompanied by the production of ascites, and patients with repeated ascites are associated with chemotherapy resistance. The previous study confirmed that the ovarian cancer patients who developed ascites after chemotherapy had elevated autophagy levels in the ascites and precipitated cells, which was positively correlated with MDR1 expression in the blood of patients. Methods In order to explore the correlation between autophagy and chemoresistant, we searched TCGA and GEO database to analyze the correlation between LC3B and MDR1, and identified the targeting miRNA of LC3B. It was verified by dual luciferase that miR-204 can target LC3B. The ovarian cancer cell line and the BALB/c nude mice tumor-bearing model were selected for in vitro and in vivo verification. In vitro studies confirmed that ovarian cancer cells were more sensitive to cisplatin by inhibiting LC3B. Results Overexpression of miR-204 reduced the expression of LC3B, Atg7, and MDR1, and promoted apoptosis. In vivo studies have also confirmed that reducing the level of autophagy in ovarian cancer cells increases the sensitivity to cisplatin. Conclusions It suggests that miR-204 can be used as a tumor suppressor gene and LC3B expression level can be used as a potential molecular marker to guide the diagnosis and treatment of patients with ovarian cancer.

【 授权许可】

Unknown